BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis
BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis
复制标题
DOI：
10.1016/j.vaccine.2020.08.045
复制
发表时间：
2020-09-22
期刊：
影响因子：
5.5
通讯作者：
Sakagami, Takuro
中科院分区：
文献类型：
--
作者：
Tomita, Yusuke;Sato, Ryo;Sakagami, Takuro
世界正面临日益严重的SARS-CoV-2危机。COVID-19疫情爆发引发全球公共卫生及经济危机。最近的流行病学研究显示，卡介苗接种计划可能与降低COVID-19相关风险有关，表明卡介苗可能提供针对COVID-19的保护。针对病毒感染的非特异性保护被认为是BCG的主要机制，目前正在进行临床试验以确定BCG疫苗是否可以保护医护人员免受COVID-19的影响。我们假设BCG可能携带与SARS-CoV-2相似的T细胞表位，并通过利用公开可用的数据库和计算机算法预测人类白细胞抗原（HLA）I类结合肽来评估这一假设。我们发现BCG含有与SARS-CoV-2相似的9个氨基酸序列。这些密切相关的肽对多种常见的HLA I类分子具有中度至高度的结合亲和力，这表明BCG疫苗接种可以产生针对SARS-CoV-2的交叉反应性T细胞。(C)2020年，任作家。由爱思唯尔有限公司发布
The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 has caused a global public health and economic crisis. Recent epidemiological studies have shown that a possible association of BCG vaccination program with decreased COVID-19-related risks, suggesting that BCG may provide protection against COVID-19. Non-specific protection against viral infections is considered as a main mechanism of BCG and clinical trials to determine whether BCG vaccine can protect healthcare workers from the COVID-19 are currently underway. We hypothesized that BCG may carry similar T cell epitopes with SARS-CoV-2 and evaluated the hypothesis by utilizing publicly available database and computer algorithms predicting human leukocyte antigen (HLA) class I-binding peptides. We found that BCG contains similar 9-amino acid sequences with SARS-CoV-2. These closely-related peptides had moderate to high binding affinity for multiple common HLA class I molecules, suggesting that cross-reactive T cells against SARS-CoV-2 could be generated by BCG vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.